Business Trends– category –
-
Synthetic Biology Firm Syntax Bio Expands Series A to $14.4M, Boosting Preclinical Research for CRISPR-Based Type 1 Diabetes Beta-Cell Therapy
Fierce Biotech USA Overview Synthetic biology company Syntax Bio announced an expansion of its Series A funding round to $14.4 million, pushing total capital raised over $25 million. This capital injection will primarily drive the develo... -
Takeda Exits Cell Therapy, Shifts Strategy to AI Drug Discovery with Additional 4,500 Job Cuts in Restructuring
BioSpace USA Overview Takeda Pharmaceutical Company is undergoing a major restructuring, including a complete exit from cell therapy, to navigate 'existential risks,' shifting its focus to 'frontier science' such as AI-driven drug discov... -
Prime Medicine Secures NZ Clinical Trial Clearance for Prime Editing Therapy PM577a in H1069Q-Mutated Wilson Disease, Initiating Global Phase 1/2 Study
GlobeNewswire (Prime Medicine Press Release) USA Overview Prime Medicine has announced the approval of its Clinical Trial Application (CTA) in New Zealand for PM577a, an investigational prime editing therapy for H1069Q-mutated Wilson dis... -
CAR-T Expands to Solid Tumors & Autoimmune Diseases; BAF CAR-T Shows Promising Early Results for Lupus, Compared with Off-the-Shelf CAR-NK Cells
University Hospitals USA Overview CAR-T cell therapy is expanding its success from hematologic malignancies to solid tumors and autoimmune diseases. Notably, early clinical trial results for BAF CAR-T in lupus are highly promising, sugge... -
Fate Therapeutics’ iPSC-Derived CAR-T FT836 Shows Early Phase 1 Data Suggesting Colorectal Tumor Shrinkage with Nine Engineered Edits
CRISPR Medicine News USA Overview Fate Therapeutics has announced initial Phase 1 data for FT836, an iPSC-derived, off-the-shelf CAR-T cell therapy. In a trial involving nine colorectal cancer patients, reductions in target lesion size a... -
Sartorius and LFB BIOMANUFACTURING Broaden Partnership to Offer Integrated Cell Line Development-to-GMP Services
PharmaSource Global Overview Sartorius and LFB BIOMANUFACTURING have expanded their strategic collaboration to provide integrated services spanning cell line development to GMP drug substance manufacturing. This partnership aims to simpl... -
Minaris Expands GMP Cell Banking Capabilities in Philadelphia, Enhancing Cell & Gene Therapy CDMO Services
Contract Pharma USA Overview Minaris has significantly enhanced its GMP cell banking suite at its Philadelphia facility, expanding its cell and gene therapy (CGT) CDMO services. This upgrade enables comprehensive support for clinical and... -
Beam Therapeutics Gains FDA IND Approval for In Vivo Base Editing Therapy BEAM-304 for PKU
CRISPR Medicine News USA Overview Beam Therapeutics has received U.S. FDA Investigational New Drug (IND) approval for BEAM-304, an in vivo base editing therapy targeting phenylketonuria (PKU). This therapy utilizes adenine base editing d... -
Tacit Knowledge Loss in Cell & Gene Therapy Tech Transfer Poses Critical Threat to Manufacturing Yield and Quality
Drug Discovery and Development USA Overview The transfer of cell and gene therapy manufacturing processes is severely hampered by the loss of tacit knowledge, impacting product yield and quality. Manual steps in CAR-T cell production, su... -
Intellia Therapeutics’ In Vivo CRISPR Therapy Lonvo-z Achieves 87% Attack Rate Reduction in HAE Phase 3 Trial, Initiates Rolling BLA Filing with FDA
Intellectia.AI USA Overview Intellia Therapeutics' in vivo CRISPR therapy, lonvo-z, demonstrated an 87% reduction in hereditary angioedema (HAE) attack frequency in its Phase 3 HAELO trial. Following these breakthrough results, the compa...
